IL162117A0 - Humanized collagen antibodies and methods utilizing the same - Google Patents

Humanized collagen antibodies and methods utilizing the same

Info

Publication number
IL162117A0
IL162117A0 IL16211702A IL16211702A IL162117A0 IL 162117 A0 IL162117 A0 IL 162117A0 IL 16211702 A IL16211702 A IL 16211702A IL 16211702 A IL16211702 A IL 16211702A IL 162117 A0 IL162117 A0 IL 162117A0
Authority
IL
Israel
Prior art keywords
same
methods utilizing
collagen antibodies
cdrs
specific binding
Prior art date
Application number
IL16211702A
Other languages
English (en)
Original Assignee
Cell Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/995,529 external-priority patent/US7365167B2/en
Application filed by Cell Matrix Inc filed Critical Cell Matrix Inc
Publication of IL162117A0 publication Critical patent/IL162117A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
IL16211702A 2001-11-26 2002-11-26 Humanized collagen antibodies and methods utilizing the same IL162117A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/995,529 US7365167B2 (en) 2001-11-26 2001-11-26 Humanized collagen antibodies and related methods
US10/011,250 US7390885B2 (en) 2001-11-26 2001-12-06 Humanized collagen antibodies and related methods
PCT/US2002/038147 WO2003046204A2 (en) 2001-11-26 2002-11-26 Humanized collagen antibodies and related methods

Publications (1)

Publication Number Publication Date
IL162117A0 true IL162117A0 (en) 2005-11-20

Family

ID=26682164

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16211702A IL162117A0 (en) 2001-11-26 2002-11-26 Humanized collagen antibodies and methods utilizing the same

Country Status (12)

Country Link
US (4) US7390885B2 (xx)
EP (1) EP1478764B1 (xx)
JP (2) JP4519464B2 (xx)
CN (1) CN1596313B (xx)
AT (1) ATE509955T1 (xx)
AU (1) AU2009200070A1 (xx)
CA (1) CA2468016A1 (xx)
HK (1) HK1076128A1 (xx)
IL (1) IL162117A0 (xx)
MX (1) MXPA04004857A (xx)
NZ (1) NZ533408A (xx)
WO (1) WO2003046204A2 (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
DE602005018325D1 (de) 2004-02-19 2010-01-28 Genentech Inc Antikörper mit korrigierten cdr
WO2007024921A2 (en) * 2005-08-24 2007-03-01 Cell Matrix Combination therapies for inhibiting integrin-extracellular matrix interactions
EP2054442A2 (en) * 2006-06-14 2009-05-06 Cell-Matrix, Inc. Denatured collagen peptides and uses thereof
JP5829004B2 (ja) * 2006-06-30 2015-12-09 ノボ・ノルデイスク・エー／エス 抗ｎｋｇ２ａ抗体とその使用
CN103408661B (zh) * 2007-01-05 2016-04-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CN101883790B (zh) 2007-10-05 2015-09-09 基因技术公司 抗淀粉样蛋白β抗体在眼病中的用途
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2359852A4 (en) * 2008-11-17 2015-05-20 Nat Cancer Ct NEW CANCERED THERAPY WITH A SUBSTANCE COMPLEX SPECIFICALLY BINDING TO A TUMOR STREAM FACTOR AND ANTITUMIR COMPOUND
DK2770327T3 (en) * 2009-03-30 2017-08-28 Nordic Bioscience As BIOMARKERING ASSAY FOR FIBROSE
CA2773356A1 (en) 2009-10-20 2011-04-28 Maine Medical Center Compositions and methods for treating inflammation and fibrosis
CA2811091C (en) * 2010-03-02 2017-07-25 Novelmed Therapeutics, Inc. A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
KR20130135869A (ko) * 2010-11-10 2013-12-11 니폰 가야꾸 가부시끼가이샤 항 단쇄 제4형 콜라겐 폴리펩타이드 항체 및 이를 포함하는 종양의 진단, 예방 또는 치료용 약제
CA2846322A1 (en) * 2011-09-19 2013-03-28 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
USRE49477E1 (en) 2012-04-20 2023-03-28 Thomas Jefferson University Engineered antibody for inhibition of fibrosis
US9926366B2 (en) 2012-10-04 2018-03-27 Novelmed Therapeutics, Inc. Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies
CN105209493B (zh) 2013-03-14 2019-05-03 德克萨斯州大学系统董事会 用于诊断和治疗用途的her3特异性单克隆抗体
BR112019005292A2 (pt) * 2016-09-21 2019-09-03 Nextcure Inc anticorpos para siglec-15 e métodos de uso dos mesmos.
JP2022511622A (ja) * 2018-10-16 2022-02-01 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム がんおよび他の疾患の診断および処置のための病原性細胞外マトリックスの同定および標的化
WO2020102779A1 (en) * 2018-11-16 2020-05-22 Albert Einstein College Of Medicine MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF
BR112021014420A2 (pt) * 2019-01-28 2021-09-21 Tuojie Biotech (Shanghai) Co., Ltd. Anticorpo anti-cd79b, fragmento de ligação ao antígeno do mesmo e uso farmacêutico do mesmo
WO2021252974A2 (en) * 2020-06-11 2021-12-16 Proviva Therapeutics (Hong Kong) Limited Collagen-targeted fusion proteins and antibodies
WO2022147298A1 (en) * 2020-12-31 2022-07-07 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Vascular-endothelial cadherin activating antibodies and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US91482A (en) * 1869-06-15 Improvement in harvesters
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL77133A (en) 1984-12-04 1991-01-31 Lilly Co Eli Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation
US5092885A (en) 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5320970A (en) * 1987-11-06 1994-06-14 Washington Research Foundation Detection of collagen degradation in vivo
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
ATE130517T1 (de) 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
US5871974A (en) 1990-09-28 1999-02-16 Ixsys Inc. Surface expression libraries of heteromeric receptors
JP3105629B2 (ja) 1991-04-23 2000-11-06 サングスタット メディカル コーポレイション 特異的結合ペアのメンバーの細胞活性調節接合体
EP0528767B1 (en) 1991-08-21 2000-01-12 Novartis AG Antibody derivatives
DE4127790A1 (de) 1991-08-22 1993-02-25 Wank Anna Verwendung von oligopeptiden mit 2 bis 5 peptidbindungen fuer kosmetische zwecke und einige neue oligopeptid-metallkomplexe
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
JPH0675216A (ja) 1992-08-27 1994-03-18 Hitachi Ltd 液晶表示装置
CA2148132A1 (en) 1992-12-04 1994-06-23 Anthony Robin Poole Immunoassay for the measurement of collagen cleavage in cartilage
US6132976A (en) * 1992-12-04 2000-10-17 Shriners Hospitals For Children Immunoassays for the measurement of collagen denaturation and cleavage in cartilage
US5541295A (en) * 1993-02-12 1996-07-30 The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations Detection of type II collagen and its peptides
ATE168779T1 (de) 1993-07-28 1998-08-15 Boehringer Mannheim Gmbh Immunoassay zum nachweis von kollagen typ i oder kollagenfragmenten davon
US5510391A (en) 1993-10-22 1996-04-23 Mayapple Holdings, Llc Method of treating blood vessel disorders of the skin using vitamin K
US5465826A (en) 1994-02-24 1995-11-14 Valiant Machine & Tool, Inc. Conveyor system
US5560910A (en) 1994-08-26 1996-10-01 Crandall; Wilson T. Topical anti-inflammatory composition and method
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US5763272A (en) * 1994-12-23 1998-06-09 Boehringer Mannheim Gmbh Hybridoma for producing antibody for collagen I
US5756775A (en) 1995-12-13 1998-05-26 Eli Lilly And Company Process to make α,α-difluoro-β-hydroxyl thiol esters
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
AU2804297A (en) 1996-04-22 1997-11-12 Advanced Polymer Systems Inc. Method of and composition for treating disorders of the skin using vitamin k
WO1997044059A2 (en) 1996-05-23 1997-11-27 Shriner's Hospitals For Children Cartilage type ii collagen as an angiogenic factor
US6492508B1 (en) 1996-06-03 2002-12-10 United States Surgical Corp. A Division Of Tyco Healthcare Group Nucleic acids encoding extracellular matrix proteins
WO1999011208A1 (en) 1997-08-28 1999-03-11 Williams C Donald Method and composition for transdermal administration of pharmacologic agents
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
GB9702252D0 (en) 1997-02-06 1997-03-26 Univ Sheffield Medical The Sch Collagen assay
US5817699A (en) 1997-05-30 1998-10-06 Flores; John A. Process for the preparation of ketamine ointment
US5972623A (en) 1997-07-31 1999-10-26 Metra Biosystems, Inc. Collagen-peptide assay method
EP1007967A2 (en) 1997-08-04 2000-06-14 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
US6030792A (en) 1997-11-13 2000-02-29 Pfizer Inc Assays for measurement of protein fragments in biological media
EP1123398B1 (en) 1998-10-16 2005-08-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Molecular pathogenicide mediated plant disease resistance
US6833373B1 (en) * 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
JP2002539076A (ja) 1999-01-06 2002-11-19 ユニバーシティ・オブ・サザン・カリフォルニア 新脈管形成抑制のための方法および組成物
US6521593B1 (en) 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
EP1203025B1 (en) 1999-07-13 2009-07-01 University Of Southern California Novel method and composition for inhibition of angiogenesis using antagonists based on mmp-9 and beta1 integrins
AU760486B2 (en) 1999-10-13 2003-05-15 Incyte Genomics, Inc. Multiplex cytokine analysis
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
CA2399080C (en) 2000-02-03 2013-05-21 Millennium Pharmaceuticals, Inc. Humanized anti-ccr2 antibodies and methods of use therefor
WO2001066144A2 (en) 2000-03-08 2001-09-13 Rhode Island Hospital, A Lifespan Partner Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
US6696254B2 (en) 2001-11-21 2004-02-24 Kimberly-Clark Worldwide, Inc. Detection and identification of enteric bacteria
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US20040241776A1 (en) 2003-05-22 2004-12-02 Agdia, Inc. Multiplex enzyme-linked immunosorbent assay for detecting multiple analytes
JP2005347062A (ja) 2004-06-02 2005-12-15 Hitachi Displays Ltd バックライト装置及び液晶表示装置
JP2006075216A (ja) 2004-09-07 2006-03-23 Toshiba Corp 医用画像処理システム、医用画像処理プログラムおよび医用画像処理方法
EP2054442A2 (en) 2006-06-14 2009-05-06 Cell-Matrix, Inc. Denatured collagen peptides and uses thereof

Also Published As

Publication number Publication date
NZ533408A (en) 2006-06-30
WO2003046204A3 (en) 2004-09-23
AU2009200070A1 (en) 2009-02-05
US20100303726A1 (en) 2010-12-02
CA2468016A1 (en) 2003-06-05
CN1596313A (zh) 2005-03-16
US7566770B2 (en) 2009-07-28
US7390885B2 (en) 2008-06-24
HK1076128A1 (en) 2006-01-06
US20070077199A1 (en) 2007-04-05
US20080260733A1 (en) 2008-10-23
JP2009240324A (ja) 2009-10-22
JP4519464B2 (ja) 2010-08-04
ATE509955T1 (de) 2011-06-15
EP1478764B1 (en) 2011-05-18
EP1478764A4 (en) 2007-05-23
JP2005510246A (ja) 2005-04-21
US20080050388A1 (en) 2008-02-28
AU2002360439A1 (en) 2003-06-10
EP1478764A2 (en) 2004-11-24
US7763248B2 (en) 2010-07-27
AU2002360439A2 (en) 2003-06-10
MXPA04004857A (es) 2005-04-11
CN1596313B (zh) 2010-05-26
WO2003046204A8 (en) 2004-07-08
WO2003046204A2 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
HK1076128A1 (en) Humanized collagen antibodies and related methods
IN2009KN02655A (xx)
WO2003100008A3 (en) Neutralizing human anti-igfr antibody
WO2003004648A1 (fr) Anticorps bispecifique anticancer de l'ovaire humain-anti cd3
WO2005069970A3 (en) Antibody specificity transfer using minimal essential binding determinants
IL220128A0 (en) Method for the humanization of antibodies and humanized antibodies thereby obtained
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
AU3117201A (en) Methods and compositions for generating human monoclonal antibodies
WO2006096491A3 (en) Anti-ctla-4 antibody compositions
MXPA01010739A (es) Anticuerpos especificos y fragmentos de anticuerpo para el factor de crecimiento transformante beta-1.
GEP20074222B (en) Antibodies to cd40
RS80704A (xx) ANTI-αvβ6 ANTITELA
GB2383331A (en) Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof
NZ593068A (en) IL-18 antibody
EP2186884A3 (en) HCV-anti-core monoclonal antibody
WO2004022717A3 (en) Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen
WO2003087340A3 (en) Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
CA2068222A1 (en) Monoclonal antibodies
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer